Oncolytic adenovirus expressing soluble TGFΒ receptor II-Fc-mediated inhibition of established bone metastases: A safe and effective systemic therapeutic approach for breast cancer

Molecular Therapy

Volumn 19, Issue 9, 2011, Pages 1609-1618

  Hu, Zebin ^a   Gerseny, Helen ^a   Zhang, Zhenwei ^a   Chen, Yun Ju ^a   Berg, Arthur ^a   Zhang, Zhiling ^a   Stock, Stuart ^b   Seth, Prem ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALANINE AMINOTRANSFERASE; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; MHTERT PROMOTER CONTROLLED ONCOLYTIC ADENOVIRUS; ONCOLYTIC ADENOVIRUS; SOLUBLE TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2 HUMAN IMMUNOGLOBULIN G1 FC FRAGMENT FUSION PROTEIN; TARTRATE RESISTANT ACID PHOSPHATASE 5B; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; BONE DESTRUCTION; BONE MATRIX; BONE METASTASIS; BONE RADIOGRAPHY; BREAST CANCER; CACHEXIA; CANCER CELL CULTURE; CANCER MODEL; CANCER SURVIVAL; CELL ACTIVATION; CELL DEATH; CELL NUCLEUS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; FEMALE; HEART LEFT VENTRICLE; HINDLIMB; HUMAN; HUMAN CELL; LIVER CELL; LIVER HISTOLOGY; LIVER TOXICITY; METASTASIS INHIBITION; MICRO-COMPUTED TOMOGRAPHY; MITOSIS RATE; MOUSE; MULTINUCLEAR CELL; NONHUMAN; NUCLEOMEGALY; ONCOLYTIC VIROTHERAPY; OSTEOCLAST; OSTEOLYSIS; SINGLE DRUG DOSE; SYNCHROTRON; SYNCHROTRON MICRO-COMPUTED TOMOGRAPHY; SYSTEMIC THERAPY; TUMOR VOLUME; WEIGHT REDUCTION;

ADENOVIRIDAE; ANIMALIA; MUS; MUS MUSCULUS;

EID: 80052421199     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.114     Document Type: Article

References (50)

1. Cancer Facts and Figures 2010. American Cancer Society.http://www.cancer. org/Research/CancerFactsandFigures
2. Coleman, RE (2001). Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27: 165-176 (Pubitemid 32452017)
3. Lu, J, Steeg, PS, Price, JE, Krishnamurthy, S, Mani, SA, Reuben, J et al. (2009). Breast cancer metastasis: challenges and opportunities. Cancer Res 69: 4951-4953
4. Bischoff, JR, Kirn, DH, Williams, A, Heise, C, Horn, S, Muna, M et al. (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274: 373-376 (Pubitemid 26353341)
5. McCormick, F (2005). Future prospects for oncolytic therapy. Oncogene 24: 7817-7819 (Pubitemid 41670682)
6. Seth, P, Wang, ZG, Pister, A, Zafar, MB, Kim, S, Guise, T et al. (2006). Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-receptor II and human immunoglobulin Fc for breast cancer therapy. Hum Gene Ther 17: 1152-1160 (Pubitemid 44749716)
7. Crompton, AM and Kirn, DH (2007). From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. Curr Cancer Drug Targets 7: 133-139 (Pubitemid 46348627)
8. Li, JL, Liu, HL, Zhang, XR, Xu, JP, Hu, WK, Liang, M et al. (2009). A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients. Gene Ther 16: 376-382
9. Yun, CO (2008). Overcoming the extracellular matrix barrier to improve intratumoral spread and therapeutic potential of oncolytic virotherapy. Curr Opin Mol Ther 10: 356-361
10. Yamamoto, M and Curiel, DT (2010). Current issues and future directions of oncolytic adenoviruses. Mol Ther 18: 243-250
11. Casimiro, S, Guise, TA and Chirgwin, J (2009). The critical role of the bone microenvironment in cancer metastases. Mol Cell Endocrinol 310: 71-81
12. Guise, TA, Mohammad, KS, Clines, G, Stebbins, EG, Wong, DH, Higgins, LS et al. (2006). Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 12(20 Pt 2): 6213s-6216s (Pubitemid 44703792)
13. Shipitsin, M, Campbell, LL, Argani, P, Weremowicz, S, Bloushtain-Qimron, N, Yao, J et al. (2007). Molecular definition of breast tumor heterogeneity. Cancer Cell 11: 259-273 (Pubitemid 46349843)
14. Kang, Y, He, W, Tulley, S, Gupta, GP, Serganova, I, Chen, CR et al. (2005). Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci USA 102: 13909-13914 (Pubitemid 41377677)
15. Nguyen, DX, Bos, PD and Massagué, J (2009). Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9: 274-284
16. Steeg, PS and Theodorescu, D (2008). Metastasis: a therapeutic target for cancer. Nat Clin Pract Oncol 5: 206-219 (Pubitemid 351493680)
17. Onishi, T, Hayashi, N, Theriault, RL, Hortobagyi, GN and Ueno, NT (2010). Future directions of bone-targeted therapy for metastatic breast cancer. Nat Rev Clin Oncol 7: 641-651
18. Tan, AR, Alexe, G and Reiss, M (2009). Transforming growth factor-signaling: emerging stem cell target in metastatic breast cancer? Breast Cancer Res Treat 115: 453-495
19. Biswas, S, Criswell, TL, Wang, SE and Arteaga, CL (2006). Inhibition of transforming growth factor-signaling in human cancer: targeting a tumor suppressor network as a therapeutic strategy. Clin Cancer Res 12(14 Pt 1): 4142-4146
20. Iyer, S, Wang, ZG, Akhtari, M, Zhao, W and Seth, P (2005). Targeting TGF signaling for cancer therapy. Cancer Biol Ther 4: 261-266 (Pubitemid 41357481)
21. Akhtari, M, Mansuri, J, Newman, KA, Guise, TM and Seth, P (2008). Biology of breast cancer bone metastasis. Cancer Biol Ther 7: 3-9
22. Guise, TA (2009). Breaking down bone: new insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases. Genes Dev 23: 2117-2123
23. Kang, Y, Siegel, PM, Shu, W, Drobnjak, M, Kakonen, SM, Cordón-Cardo, C et al. (2003). A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3: 537-549 (Pubitemid 36808649)
24. Padua, D and Massagué, J (2009). Roles of TGF in metastasis. Cell Res 19: 89-102
25. Gupta, J, Robbins, J, Jilling, T and Seth, P (2011). TGF-dependent induction of interleukin-11 and interleukin-8 involves SMAD and p38 MAPK pathways in breast tumor models with varied bone metastases potential. Cancer Biol Ther 11: 311-316
26. Tester, AM, Sharp, JA, Dhanesuan, N, Waltham, M and Thompson, EW (2002). Correlation between extent of osteolytic damage and metastatic burden of human breast cancer metastasis in nude mice: real-time PCR quantitation. Clin Exp Metastasis 19: 377-383 (Pubitemid 34876205)
27. Kingsley, LA, Fournier, PG, Chirgwin, JM and Guise, TA (2007). Molecular biology of bone metastasis. Mol Cancer Ther 6: 2609-2617 (Pubitemid 350058141)
28. Hu, Z, Zhang, Z, Guise, T and Seth, P (2010). Systemic delivery of an oncolytic adenovirus expressing soluble transforming growth factor-receptor II-Fc fusion protein can inhibit breast cancer bone metastasis in a mouse model. Hum Gene Ther 21: 1623-1629
29. Hu, Z, Robbins, JS, Pister, A, Zafar, MB, Zhang, ZW, Gupta, J et al. (2010). A modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGF signaling for breast cancer therapy. Cancer Gene Ther 17: 235-243
30. Janckila, AJ, Nakasato, YR, Neustadt, DH and Yam, LT (2003). Disease-specific expression of tartrate-resistant acid phosphatase isoforms. J Bone Miner Res 18: 1916-1919 (Pubitemid 37322575)
31. Howe, JA, Demers, GW, Johnson, DE, Neugebauer, SE, Perry, ST, Vaillancourt, MT et al. (2000). Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy. Mol Ther 2: 485-495
32. Huang, TG, Savontaus, MJ, Shinozaki, K, Sauter, BV and Woo, SL (2003). Telomerasedependent oncolytic adenovirus for cancer treatment. Gene Ther 10: 1241-1247 (Pubitemid 36934726)
33. Kuroda, S, Fujiwara, T, Shirakawa, Y, Yamasaki, Y, Yano, S, Uno, F et al. (2010). Telomerase-dependent oncolytic adenovirus sensitizes human cancer cells to ionizing radiation via inhibition of DNA repair machinery. Cancer Res 70: 9339-9348
34. Kim, E, Kim, JH, Shin, HY, Lee, H, Yang, JM, Kim, J et al. (2003). Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum Gene Ther 14: 1415-1428 (Pubitemid 37268220)
35. Kishimoto, H, Urata, Y, Tanaka, N, Fujiwara, T and Hoffman, RM (2009). Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses. Mol Cancer Ther 8: 3001-3008
36. Kishimoto, H, Zhao, M, Hayashi, K, Urata, Y, Tanaka, N, Fujiwara, T et al. (2009). In vivo internal tumor illumination by telomerase-dependent adenoviral GFP for precise surgical navigation. Proc Natl Acad Sci USA 106: 14514-14517
37. Nemunaitis, J, Tong, AW, Nemunaitis, M, Senzer, N, Phadke, AP, Bedell, C et al. (2010). A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Ther 18: 429-434
38. Hoffman, RM (2005). The multiple uses of fluorescent proteins to visualize cancer in vivo. Nat Rev Cancer 5: 796-806 (Pubitemid 41400779)
39. Hoffman, RM (1999). Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 17: 343-359 (Pubitemid 30135902)
40. Kalyuzhniy, O, Di Paolo, NC, Silvestry, M, Hofherr, SE, Barry, MA, Stewart, PL et al. (2008). Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci USA 105: 5483-5488 (Pubitemid 351753889)
41. Waddington, SN, McVey, JH, Bhella, D, Parker, AL, Barker, K, Atoda, H et al. (2008). Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132: 397-409 (Pubitemid 351200513)
42. Seth, P (ed) (1999). Adenoviruses: Basic Biology to Gene Therapy. RG Landes Company: Austin, TX
43. Engler, H, Machemer, T, Philopena, J, Wen, SF, Quijano, E, Ramachandra, M et al. (2004). Acute hepatotoxicity of oncolytic adenoviruses in mouse models is associated with expression of wild-type E1a and induction of TNF-alpha. Virology 328: 52-61 (Pubitemid 39221912)
44. Schowalter, DB, Himeda, CL, Winther, BL, Wilson, CB and Kay, MA (1999). Implication of interfering antibody formation and apoptosis as two different mechanisms leading to variable duration of adenovirus-mediated transgene expression in immunecompetent mice. J Virol 73: 4755-4766 (Pubitemid 29246735)
45. Katayose, D, Gudas, J, Nguyen, H, Srivastava, S, Cowan, KH and Seth, P (1995). Cytotoxic effects of adenovirus-mediated wild-type p53 protein expression in normal and tumor mammary epithelial cells. Clin Cancer Res 1: 889-897
46. Bett, AJ, Krougliak, V and Graham, FL (1995). DNA sequence of the deletion/insertion in early region 3 of Ad5 dl309. Virus Res 39: 75-82
47. Yin, JJ, Selander, K, Chirgwin, JM, Dallas, M, Grubbs, BG, Wieser, R et al. (1999). TGF-signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103: 197-206 (Pubitemid 29053137)
48. Erlebacher, A and Derynck, R (1996). Increased expression of TGF-2 in osteoblasts results in an osteoporosis-like phenotype. J Cell Biol 132: 195-210
49. Stock, SR (ed) (2008). MicroComputed Tomography: Methodology and Applications. Taylor and Francis
50. Wang, YX, Carlo, FD, Mancini, DC, McNulty, I, Tieman, B, Bresnahan, J et al (2001). A high-throughput X-ray microtomography system at the Advanced Photon Source. Rev Sci Instrum 72: 2062-2068 (Pubitemid 33606062)